Archive · 26 Jan 2026
Delhi High Court Restores Ban on Diabetes FDCs
The Delhi High Court has recently restored a ban on two diabetes medicines that combine multiple drugs, including one called pioglitazone.
These medicines, known as fixed dose combinations (FDCs), mix several drugs into one pill.
The court's decision was made to protect public health, as some experts believe these combinations are not always safe or necessary.
Pioglitazone, one of the drugs in these FDCs, has been linked to heart problems, bone issues, and even bladder cancer.
Some doctors argue that these FDCs are not crucial and that there are other, safer options available.
The court's ruling has sparked discussions among health professionals and the pharmaceutical industry.
Delhi High Court restored a ban on two diabetes FDCs containing pioglitazone, upholding public health interests.
The ban was previously lifted by a single judge but was reinstated after a caveat was filed in the Supreme Court.
Pioglitazone is associated with risks such as heart failure, bone density loss, and bladder cancer.
Experts argue that these FDCs are not crucial and there are safer alternatives available.
The court's decision has sparked discussions among medical practitioners and public health workers.
- Who
- Delhi High Court, Micro Labs, Intas Pharmaceuticals, Lupin, Eris Lifesciences, All India Drug Action Network (Aidan)
- What
- Restoration of ban on two diabetes FDCs containing pioglitazone
- When
- January 2026
- Where
- Delhi, India
- Why
- In the interest of public health and rationality of products
- Court
- Delhi High Court
- Drugs Banned
- Two diabetes FDCs containing pioglitazone
- Companies Involved
- Micro Labs, Intas Pharmaceuticals, Lupin, Eris Lifesciences
- Date of Judgement
- January 2026
- Expert Opinion
- Pioglitazone poses risks like heart failure, bone density loss, and bladder cancer